Viewing Study NCT03342300

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 12:14 PM
Ignite Modification Date: 2026-02-24 @ 3:14 PM
Study NCT ID: NCT03342300
Status: WITHDRAWN
Last Update Posted: 2020-05-19
First Post: 2017-11-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Sponsor: Peking University People's Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Progression-free Survival View
None Overall Survival View
None Toxicity View
Keywords:

Keywords

Keyword Brief Keyword Text View
None soft tissue sarcoma View
None pegylated liposomal doxorubicin View
None pirarubicin View
None toxicity for heart View
None cumulative dose View